{"version":"1.0","type":"link","title":"Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience.","author_name":"Basile G 외","author_url":"https://prs-insight.online/author/Basile%20G","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/158335","thumbnail_width":1200,"thumbnail_height":630}